Ironwood will purchase all of VectivBio’s outstanding ordinary shares for $17.00/share in cash with an estimated consideration of ~$1B representing an 80% premium on the company’s avg. trading price over the previous 90 trading days. The transaction is expected to close in H2’23
The acquisition will strengthen Ironwood’s innovative portfolio and pipeline to advance the treatment of GI diseases along with supporting long-term profitability & cash-flow generation
VectivBio’s apraglutide, a next-generation, GLP-2 analog is currently in P-III for short bowel syndrome with intestinal failure (SBS-IF) which will assess clinical benefit for both SBS-IF stoma and colon-in-continuity patients & results are expected at the end of 2023
Ref: Businesswire | Image: Ironwood
Related News:- Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
